Latest News
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
June 24, 2025
Two USFDA inspections in ophthalmology, with ZERO 483
Proud Moment
Delighted to share that we have successfully completed two USFDA inspections in ophthalmology, with ZERO 483!
This achievement reflects our team’s unwavering commitment to quality, compliance, and patient safety in every step of the research journey.
A big thank you to our incredible team whose hard work, integrity, and attention to detail made this achievement possible. Your dedication ensures we continue to meet the highest global standards in advancing vision science and improving patient outcomes.
Looking forward to continuing our mission to drive innovation in ophthalmic research with the same passion and precision.
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Sanjeev Ganatra Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas
#USFDA #ClinicalTrials #RegulatoryExcellence #Ophthalmology #ResearchIntegrity #GCP #Teamwork #PatientSafety #ClinicalResearch